Current approaches and challenges for monitoring treatment response in colon and rectal cancer

Journal of Cancer

Volumn 5, Issue 1, 2014, Pages 31-43

  McKeown, Elizabeth ^a   Nelson, Daniel W ^b   Johnson, Eric K ^b   Maykel, Justin A ^c   Stojadinovic, Alexander ^d   Nissan, Aviram ^e   Avital, Itzhak ^f   Brücher, Björn L D M ^f   Steele, Scott R ^b  

^a SWEDISH MEDICAL CENTER   (United States)

^b Madigan Army Hospital   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f Bon Secours Cancer Institute   (United States)

Author keywords

CEA; Colorectal cancer; CT; Down staging; ERUS; Imaging modalities; MRI; Neoadjuvant therapy; PET; Treatment response

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; ENDOSCOPY; GOLD STANDARD; HUMAN; LYMPH NODE DISSECTION; MEDICAL LITERATURE; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CANCER; REVIEW; TREATMENT RESPONSE;

EID: 84893547743     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7987     Document Type: Review

References (116)

1. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute. 2012.
2. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Annals of surgery. 1979;189(4):496-502.
3. Borner MM. Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 1999;10(6):623-626.
4. Lawes D, Boulos PB. Advances in the management of rectal cancer. Journal of the Royal Society of Medicine. 2002;95(12):587-590.
5. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. American journal of clinical oncology. 2001;24(2):107-112.
6. Cukier M, Smith AJ, Milot L, et al. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2012;38(8):677-682.
7. Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Diseases of the colon and rectum. 2013;56(6):698-703.
8. Beck DE. American Society of Colon and Rectal Surgeons. The ASCRS manual of colon and rectal surgery. New York, NY: Springer; 2009.
9. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management: a review of contemporary primary rectal cancer treatment strategies. CA: a cancer journal for clinicians. 2012;62(3):173-202.
10. Milsom JW, Bohm B, Hammerhofer KA, Fazio V, Steiger E, Elson P. A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report. Journal of the American College of Surgeons. 1998;187(1):46-54; discussion 54-45.
11. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.2004;22(2):229-237.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009;59(4):225-249.
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(1):23-30.
14. Marin JJ, Sanchez de Medina F, Castano B, et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug metabolism reviews. 2012;44(2):148-172.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. Jun 3 2004;350(23):2335-2342.
16. Ahmed SL, et al. Survival impact of surgical resection of primary tumor (SRPT) in metastatic colorectal cancer (mCRC): A population-based cohort study. J Clin Oncol 2012; 30: (suppl 34): abstr456.
17. Fahrni AMR. Effect of primary tumor resection on survival in patients with metastatic colorectal cancer in the post-2000 era: A California Cancer Registry analysis. J Clin Oncol 2012; 30: (suppl 34): abstr504.
18. Gresham GR, et al. The impact of palliative resection of the primary tumor on overall survival in metastatic colorectal cancer. 2013.
19. McCahill LY, et al. A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab for patients with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis. 2013.
20. Wong SF, et al. Metastatic colorectal cancer (mCRC) with primary in situ: An Australian Registry. 2013.
21. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(28):7125-7134.
22. Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. International journal of surgical oncology. 2011;2011:285840.
23. Holleb AI. William Ernest Miles (1869-1947). CA: a cancer journal for clinicians. 1971;21(6):360.
24. Allal AS, Bieri S, Pelloni A, et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. British journal of cancer. 2000;82(6):1131-1137.
25. Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Annals of surgery. 1988;208(5):606-614.
26. Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoperative irradiation in operable cancer of the rectum: report of the Toronto trial. Canadian journal of surgery. Journal canadien de chirurgie. 1977;20(4):335-338.
27. [No authors listed]. The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer; results of a randomly controlled trial. The British journal of surgery. 1984;71(1):21-25.
28. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. The New England journal of medicine. 1997;336(14):980-987.
29. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17(8):2396.
30. Gambacorta MA, Valentini V, Morganti AG, et al. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study. International journal of radiation oncology, biology, physics. 2004;60(1):130-138.
31. Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. International journal of radiation oncology, biology, physics. 2001;49(4):987-995.
32. Rengan R, Paty P, Wong WD, et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(22):4905-4912.
33. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England journal of medicine. 2004;351(17):1731-1740.
34. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(16):1926-1933.
35. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. International journal of radiation oncology, biology, physics. 1998;40(5):1067-1075.
36. Group MS. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Bmj. 2006;333(7572):779.
37. Brown G, Davies S, Williams GT, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? British journal of cancer. 2004;91(1):23-29.
38. Guillem JG, Chessin DB, Shia J, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(15):3475-3479.
39. Kirat HT, Ozturk E, Lavery IC, Kiran RP. The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. American journal of surgery. 2012;204(4):447-452.
40. Fletcher RH. Carcinoembryonic antigen. Annals of internal medicine. 1986;104(1):66-73.
41. Jang NY, Kang SB, Kim DW, et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Diseases of the colon and rectum. 2011;54(2):245-252.
42. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical chemistry. 2008;54(12):e11-79.
43. Perez RO, Sao Juliao GP, Habr-Gama A, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Diseases of the colon and rectum. 2009;52(6):1137-1143.
44. Willkomm P, Bender H, Bangard M, Decker P, Grunwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2000;41(10):1657-1663.
45. Libutti SK, Alexander HR, Jr., Choyke P, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Annals of surgical oncology. 2001;8(10):779-786.
46. Cohen AM, Martin EW, Jr., Lavery I, et al. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Archives of surgery. 1991;126(3):349-352.
47. Kim JC, Kim WS, Ryu JS, et al. Applicability of carcinoembryonic antigen- specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma. Cancer research. 2000;60(17):4825-4829.
48. Zitt M, Zitt M, Muller HM. DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities? Disease markers. 2007;23(1-2):51-71.
49. Ahn JB, Chung WB, Maeda O, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011;117(9):1847-1854.
50. Soldevilla B, Diaz R, Silva J, et al. Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(18):6029-6039.
51. Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Current treatment options in oncology. 2010;11(1-2):1-13.
52. Lu CY, Uen YH, Tsai HL, et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. British journal of cancer. 2011;104(7):1178-1184.
53. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(3):529-536.
54. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology. 2004;232(3):773-783.
55. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. The British journal of surgery. 2010;97(4):580-587.
56. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. The British journal of surgery. 2008;95(12):1534-1540.
57. Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP, Lyons Oncology G. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. The British journal of surgery. 2003;90(8):996-998.
58. Valentini V, Glimelius B. Rectal cancer radiotherapy: towards European consensus. Acta oncologica. 2010;49(8):1206-1216.
59. Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2005;9(1):90-99; discussion 99-101.
60. Lahaye MJ, Beets GL, Engelen SM, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology. 2009;252(1):81-91.
61. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2004;45(9):1509-1518.
62. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227(2):371-377.
63. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. International journal of colorectal disease. 2000;15(1):9-20.
64. Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET Nor CT Is Able to Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study. Annals of surgery. 2012.
65. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000;92(3):205-216.
66. Monteil J, Mahmoudi N, Leobon S, et al. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer research. 2009;29(7):2563-2568.
67. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(20):3245-3251.
68. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2000;41(7):1177-1189.
69. Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health technology assessment. 2011;15(35):1-192.
70. Dobos N, Rubesin SE. Radiologic imaging modalities in the diagnosis and management of colorectal cancer. Hematology/oncology clinics of North America. 2002;16(4):875-895.
71. National Collaborating Centre for Cancer (UK). Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer. Cardiff: National Collaborating Centre for Cancer (UK). 2011.
72. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and [18F]-FDG in oncology: a clinical update. Nuclear medicine and biology. 1996;23(6):717-735.
73. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1999;40(4):591-603.
74. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1997;38(8):1196-1201.
75. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Annals of surgery. 1998;227(3):319-323.
76. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Archives of surgery. 1996;131(7):703-707.
77. Capirci C, Rubello D, Chierichetti F, et al. Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2004;58(8):451-457.
78. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Diseases of the colon and rectum. 2008;51(1):21-25.
79. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? European radiology. 2005;15(8):1658-1666.
80. O'Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. The lancet oncology. 2007;8(7):625-633.
81. Dewhurst CE, Mortele KJ. Magnetic resonance imaging of rectal cancer. Radiologic clinics of North America. 2013;51(1):121-131.
82. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. The British journal of surgery. 2003;90(3):355-364.
83. Patel UB, Blomqvist LK, Taylor F, et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response--the MERCURY experience. AJR. American journal of roentgenology. 2012;199(4):W486-495.
84. Kim NK, Baik SH, Min BS, et al. A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. International journal of radiation oncology, biology, physics. 2007;67(1):204-210.
85. Kang JH, Kim YC, Kim H, et al. Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathologic complete response. International journal of radiation oncology, biology, physics. 2010;76(4):1018-1025.
86. Kluza E, Rozeboom ED, Maas M, et al. T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer. European radiology. 2013;23(1):253-261.
87. Kuo LJ, Chiou JF, Tai CJ, et al. Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? International journal of colorectal disease. 2012;27(5):613-621.
88. Edelman BR, Weiser MR. Endorectal ultrasound: its role in the diagnosis and treatment of rectal cancer. Clinics in colon and rectal surgery. 2008;21(3):167-177.
89. Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? Diseases of the colon and rectum. 2011;54(9):1141-1146.
90. Kav T, Bayraktar Y. How useful is rectal endosonography in the staging of rectal cancer? World journal of gastroenterology: WJG. 2010;16(6):691-697.
91. Fernandez-Esparrach G, Ayuso-Colella JR, Sendino O, et al. EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative study. Gastrointestinal endoscopy. 2011;74(2):347-354.
92. Maor Y, Nadler M, Barshack I, et al. Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiation. Journal of gastroenterology and hepatology. 2006;21(2):454-458.
93. Napoleon B, Pujol B, Berger F, Valette PJ, Gerard JP, Souquet JC. Accuracy of endosonography in the staging of rectal cancer treated by radiotherapy. The British journal of surgery. 1991;78(7):785-788.
94. Assenat E, Thezenas S, Samalin E, et al. The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower- third rectal adenocarcinoma. Endoscopy. 2007;39(4):309-313.
95. Gavioli M, Bagni A, Piccagli I, Fundaro S, Natalini G. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: comparison between sonographic and histopathologic changes. Diseases of the colon and rectum. 2000;43(8):1075-1083.
96. Rovera F, Dionigi G, Boni L, Cutaia S, Diurni M, Dionigi R. The role of EUS and MRI in rectal cancer staging. Surgical oncology. 2007;16 Suppl 1:S51-52.
97. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. Journal of the American College of Surgeons. 2002;194(2):131-135; discussion 135-136.
98. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Diseases of the colon and rectum. 2008;51(1):10-19; discussion 19-20.
99. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(35):4633-4640.
100. Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Annals of surgery. 2012;256(6):965-972.
101. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. International journal of colorectal disease. 1997;12(1):19-23.
102. MacGregor TP, Maughan TS, Sharma RA. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. Journal of clinical pathology. 2012;65(10):867-871.
103. Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Archives of pathology & laboratory medicine. 2009;133(10):1539-1551.
104. Park YJ, Oh BR, Lim SW, et al. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. Journal of the Korean Society of Coloproctology. 2010;26(4):279-286.
105. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(34):8688-8696.
106. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. The British journal of surgery. 2012;99(7):918-928.
107. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. The lancet oncology. 2010;11(9):835-844.
108. Matrai Z, Lovey J, Hitre E, et al. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature]. Orvosi hetilap. 22 2006;147(42):2011-2020.
109. Hughes R, Glynne-Jones R, Grainger J, et al. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? International journal of colorectal disease. 2006;21(1):11-17.
110. Chan G, Hassanain M, Chaudhury P, et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2010;12(4):277-284.
111. Chennupati SK, Quon A, Kamaya A, et al. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. American journal of clinical oncology. 2012;35(4):334-339.
112. Group MS. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132-139.
113. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. European journal of nuclear medicine and molecular imaging. 2007;34(6):878-883.
114. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Annals of surgery. 2004;240(4):711-717; discussion 717-718.
115. Maretto I, Pomerri F, Pucciarelli S, et al. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Annals of surgical oncology. 2007;14(2):455-461.
116. Intven M, Reerink O, Philippens ME. Diffusion-weighted MRI in locally advanced rectal cancer: pathological response prediction after neo-adjuvant radiochemotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. 2013;189(2):117-122.